TABLE 2a.
AstraZeneca | Janssen | Moderna | Pfizer-BioNTech | |||||||
---|---|---|---|---|---|---|---|---|---|---|
CTC | Influenza cases | R n | Cases | R c | Cases | R c | Cases | R c | Cases | R c |
Allergic | 1941 | 2.52 | 172092 | 69.80 | 12216 | 4.96 | 51360 | 20.83 | 134015 | 54.36 |
Arrythmia | 235 | 0.30 | 20614 | 8.36 | 1690 | 0.69 | 11438 | 4.64 | 32245 | 13.08 |
Haematological | 8 | 0.01 | 179 | 0.07 | 88 | 0.04 | 52 | 0.02 | 414 | 0.17 |
Cardiovascular | 159 | 0.21 | 14328 | 5.81 | 2102 | 0.85 | 8959 | 3.63 | 27679 | 11.23 |
Coagulation | 13 | 0.02 | 3392 | 1.38 | 673 | 0.27 | 532 | 0.22 | 2191 | 0.89 |
Constitutional | 1392 | 1.81 | 260666 | 105.73 | 30361 | 12.32 | 73477 | 29.80 | 223516 | 90.66 |
Dermatological | 1966 | 2.55 | 31509 | 12.78 | 4534 | 1.84 | 39148 | 15.88 | 47936 | 19.44 |
Gastrointestinal | 848 | 1.10 | 103489 | 41.98 | 7684 | 3.12 | 29897 | 12.13 | 99231 | 40.25 |
Haemorraghe | 50 | 0.06 | 4942 | 2.00 | 407 | 0.17 | 1504 | 0.61 | 4850 | 1.97 |
Neurological | 1144 | 1.48 | 93643 | 37.98 | 6680 | 2.71 | 29240 | 11.86 | 103704 | 42.06 |
Ocular | 122 | 0.16 | 15325 | 6.22 | 951 | 0.39 | 3976 | 1.61 | 13463 | 5.46 |
Localised pain | 990 | 1.28 | 47475 | 19.26 | 4936 | 2.00 | 24161 | 9.80 | 79290 | 32.16 |
Non-localised pain | 2225 | 2.89 | 251668 | 102.08 | 21036 | 8.53 | 69183 | 28.06 | 246484 | 99.98 |
Pulmonary | 455 | 0.59 | 24134 | 9.79 | 2550 | 1.03 | 14101 | 5.72 | 40103 | 16.27 |
Renal/Genitourinary | 26 | 0.03 | 816 | 0.33 | 142 | 0.06 | 877 | 0.36 | 1497 | 0.61 |
Sexual organs | 9 | 0.01 | 9926 | 4.03 | 1277 | 0.52 | 5013 | 2.03 | 26667 | 10.82 |
Thrombosis | 17 | 0.02 | 11254 | 4.56 | 2239 | 0.91 | 3257 | 1.32 | 8150 | 3.31 |
Other reactions | 8450 | 10.96 | 577904 | 234.41 | 53467 | 21.69 | 216670 | 87.89 | 683218 | 277.13 |
Denominators of Rn and Rc: 7.71 × 107 and 246,534,547 exposed individuals age 18 and older, respectively. Only the last two decimals of the risk estimates are reported.